Case Study: Global Pharmaceutical Leader achieves rapid de-risking and 4-week email security deployment with Mimecast

Pharmaceutical Leader Turns to Mimecast after Symantec Sunset

One of the world’s leading pharmaceutical companies faced a sudden risk when Broadcom’s 2019 acquisition of Symantec changed product support and strategy, prompting the company to urgently “de-risk” its email security and data-loss protection. After a rapid evaluation of vendors, the company selected Mimecast for the quality of its technology and the speed at which it could be deployed.

Mimecast provided email security with Targeted Threat Protection plus DMARC Analyzer and Brand Exploit Detection, integrating easily with Splunk and other infrastructure. The solution offered broader capabilities than the incumbent, was highly customizable, and—despite COVID-19 constraints—was deployed to tens of thousands of users in four weeks, earning high praise for Mimecast’s professional services and delivering stronger protection against threats and brand spoofing.